Dantrolene sodium ( DrugBank: Dantrolene )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 233 | ウォルフラム症候群 | 1 |
233. ウォルフラム症候群
臨床試験数 : 11 / 薬物数 : 17 - (DrugBank : 8) / 標的遺伝子数 : 12 - 標的パスウェイ数 : 41
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02829268 (ClinicalTrials.gov) | January 2017 | 6/7/2016 | A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome | A Phase 1b/2a Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome | Wolfram Syndrome;Diabetes Mellitus;Optic Nerve Atrophy;Ataxia | Drug: dantrolene sodium | Washington University School of Medicine | National Institutes of Health (NIH);National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Active, not recruiting | 5 Years | 60 Years | All | 50 | Phase 1/Phase 2 | United States |